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Highly pathogenic avian influenza (HPAI) H5N1 virus outbreaks 
continue to occur in poultry [1]. Although human cases are sporadic 
and rare, they can be severe with a sustained 60% mortality rate 
worldwide. In many cases the risk factors include contact with sick 
and dying domestic poultry. Many countries that previously declared 
themselves H5N1 virus-free have now decreed regions a crisis zone 
following identification of variant H5N1 viruses, which adversely 
impact global trade in live poultry and poultry products and render 
current poultry vaccines ineffective [2]. Moreover, virus outbreaks in 
poultry may be hidden as low pathogenicity avian influenza (LPAI) 
virus infections and vaccinated birds can be sub clinically infected 
upon exposure to field virus. Disease levels tend to be high in countries 
with poor veterinary systems and influenza-prone farming systems, 
including backyard farms, mixed poultry and pig farms, often in 
close proximity to wild ducks and other influenza virus reservoirs [3]. 
Control measures encompass culling poultry around the outbreak site, 
intensive surveillance campaigns, poultry market closures and poultry 
movement bans. However, illegal trade of poultry across borders has 
enabled movement of HPAI H5N1 virus despite biosecurity measures 
for people and vehicles moving to and from premises containing 
poultry. Control strategies emphasize vaccination of poultry in some 
nations where stamping out alone is ineffective. Such poultry vaccines 
offer a powerful tool to mitigate the high risk of transmission of avian 
influenza virus to birds and people by reducing virus shedding [4,5]. 
However, effective vaccination strategies must overcome late onset of 
immunity, poor efficacy in ducks, mismatch between field and vaccine 
strains due to emergence of escape virus variants and limited delivery 
to remote regions. Since 2003, ten clades of H5N1 virus have emerged 
despite vaccination attempts and cross-protection in poultry now varies 
widely according to the phylogenetic relationship between seed virus 
used in vaccines and circulating virus. Global surveillance for detecting 
virus outbreaks, monitoring how viruses are evolving, understanding 
risk factors that enable them to spread, and keeping bird vaccines and 
diagnostics up to date will reinforce the vaccination strategy of control 
programs for universal coverage of the large, fragmented global poultry 
industry. However, besides both vaccination and surveillance as critical 
factors to drive programs to successfully combat disease, both practical 
and effective options need to be adopted by countries to build strong 
national responses.
Currently, conventional vaccine preparations of inactivated whole 
viruses in oil emulsions are preferred options for use in poultry [6,7]. 
Vaccination of day-old chicks in the hatchery is a common practice 
as this is less labour-intensive. However, a booster vaccine is often 
required to optimize vaccine efficacy. Generally, HA-specific antibody 
responses are induced and a rise in titre to at least 16 correlates with 
protection in chickens. A rapid four fold-rise in antibody titre of 
vaccinated birds would be unexpected and suggests an anamnestic 
response to recent infection. However, classical inactivated vaccines 
have limited efficacy against variations in field virus, especially when 
antigenic variance does not produce cross protective H5 HI titres 
against the vaccine strain. Improved surveillance for detecting H5N1 
virus outbreaks in vaccinated flocks as early as possible is needed to 
prevent spread and human fatalities. Tracking virus outbreaks has 
been difficult in vaccinated flocks, as vaccinated birds do not show 
early clinical symptoms with silent infection that can be devastating 
[8,9]. Vaccination also complicates monitoring of infection by serology 
as detection of virus infection via H5 seroconversion is unable to 
Differentiate Infected from Vaccinated Animals (DIVA). Thus 
conventional vaccine use greatly limits the value of blood testing in an 
eradication program, especially in the case of LPAI viruses. Various 
strategies using serology of antigen markers to detect vaccination 
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Abstract
Highly pathogenic avian influenza (HPAI) H5N1 virus strains have emerged as zoonotic viral pathogens over 
the last decade and have eluded our serious attempts of control in domestic poultry by vaccination, with numerous 
countries continuing to have epidemic waves. Although the biology and genomics of H5N1 influenza viruses are well 
characterized so far, viral outbreaks still occur in domestic poultry, posing a dangerous threat of human transmission. 
There are two main types of contemporary inactivated vaccines, namely whole virus vaccines and virus vaccines 
engineered by reverse genetics, both of which are administered with adjuvant to hatchlings and optimally require 
a booster. However, determinants of vaccine efficacy need to be considered distinctly in chickens versus ducks 
on a country basis. There is a critical need for detection of infection and vaccination of domestic poultry to control 
potentially deadly but silent infection in vaccinated flocks. A positive vaccine marker strategy using tetanus toxoid 
offers advantages for more effective control programs of HPAI including improved capacity for early detection of virus 
outbreaks and indisputable data for surveillance of vaccinated flocks in vaccination control programs for backyard and 
village poultry, highly desirable in endemic regions.
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and infection in vaccinated flocks have been devised to overcome this 
problem [10].
A DIVA strategy that has been developed for use in Europe 
exploits a H5N2 vaccine containing a heterologous NA antigen to 
the circulating H5N1 avian influenza virus [11]. The heterologous 
NA DIVA approach is based on detection of animals with positive 
anti-N1 antibody responses before a detectable rise in the flock H5 
antibody levels but the anamnestic response in vaccinated poultry to 
H5 will develop more rapidly than the primary antibody response to 
N1. Thus, a primary antibody response to the different N subtype to 
that given in the vaccine takes a longer time to develop than a recall 
memory antibody response to the H5 antigen, allowing unmonitored 
virus spread throughout the flock. Current guidelines for serological 
DIVA testing in Europe, requiring only small sample sizes of 5-10 birds 
tested for NA antibody, would only provide assurance of detecting 
infection at the 95% confidence level if over 30% of poultry in the flock 
have been exposed to field virus [12]. This would likely take at least 
3 weeks from introduction of infection to allow detection (one week 
for the virus to infect sufficient numbers of birds in the flock and a 
further 2 weeks for development of primary antibody responses in 
infected birds), a time when infection may no longer be active in the 
flock [13]. Not all exposed vaccinated poultry will develop antibodies 
to N1 in the virulent field strain due to limited replication in vaccinated 
animals [14]. Use of homologous NA antigens in vaccines, particularly 
for ducks, precludes use of the anti-N1 DIVA strategy. Other DIVA 
approaches for poultry based on negative markers include anti-NS1 
and anti-NP antibody testing for recombinant live virus vector vaccines 
[15], including rHVT-H5, rNDV-H5 and rFPV-H5. Recently, a novel 
DIVA approach was developed using HPAI H5N1 virus-like particles 
[16]. Several disadvantages include likely contamination of whole virus 
vaccines with NS protein, reducing the value of using detection of anti-
NS1 antibodies as a negative marker. Also, anti-NP antibody testing 
cannot be used if other avian influenza viruses are circulating in the test 
population, an uncommon situation for Asia and Egypt.
A positive avian influenza marker, unlike the abovementioned 
negative marker DIVA strategies offers an improved range of capabilities 
for vaccination and infection surveillance. We have previously used a 
positive marker strategy for H5N1 vaccination of poultry and have 
evaluated vaccination of chickens and ducks for protective efficacy 
against H5N1 virus infection in the laboratory. We selected tetanus 
toxoid (TT) as the positive marker, an exogenous antigen independent 
of serotype and relatedness of circulating virus and vaccine strains. 
Birds are naturally seronegative to TT but when TT is incorporated 
into poultry vaccines for H5N1 virus, vaccinated chickens seroconvert 
[17]. Evidence of vaccination in chickens by a simple ELISA test was 
associated with high specificity and sensitivity. Importantly, protection 
afforded by the avian influenza virus TT marker vaccine was equal to 
the homologous avian influenza virus vaccine in chickens [18]. This 
positive marker strategy has the potential to be used for detection of 
silent infection in vaccinated flocks, demonstrated by the development 
of a rapid anamnestic response to H5 antigen in vaccinated chickens 
exposed to HPAI H5N1 virus. We have observed stable antibody 
responses to the TT marker lasting out to one year post-vaccination 
in chickens with no significant difference in titre between six and 53 
weeks post-vaccination, in contrast to a decline in antibody titre to AIV 
over the year post-vaccination.
Significantly, vaccination of ducks is problematic, as they are a 
natural host to a range of influenza viruses and since infection is often 
sub-clinical, little incentive exists for farmers to prevent infection in 
their flocks. Thus anti-NS1, anti-NP and anti-M antibody testing as a 
DIVA approach cannot be used in ducks. Furthermore, the anti-N1 
DIVA strategy has not been evaluated in ducks despite ducks being 
the largest poultry market in China and Vietnam. We validated the 
TT marker approach in ducks and found that H6N2/TT vaccination 
induced TT seroconversion in twice-vaccinated Muscovy ducks, which 
persisted out to 19 weeks in contrast to a decline in antibody titre 
to AIV after 6 weeks post-vaccination [19]. Evidence of TT marker 
vaccination in ducks was performed using a competitive ELISA and a 
vaccine dose double that used for chickens, as ducks are well known to 
be poor antibody responders. Ducklings receive H5 vaccination in the 
hatchery, with maternal immunity waning by 3 weeks, and optimally 
require a boost for antibody responses to H5. In our laboratory study, 
Peking ducks vaccinated with a commercially available inactivated 
H5N2 whole virus vaccine (Nobilis) produced detectable H5 HI 
antibodies by 3 weeks post-vaccination, which steadily increased in titre 
over a five-week period. Importantly, protection against HPAI H5N1 
virus afforded by the avian influenza virus marker vaccine (TT/H5N2) 
was equal to the homologous avian influenza virus vaccine (H5N2) in 
ducks and did not interfere with antibody responses to influenza virus 
antigens contained in the vaccine [20]. Therefore, evaluation studies 
of the TT marker for avian influenza vaccination encompassed LPAI 
H6N2 and HPAI H5N1 vaccinated ducks in Australia and Hong Kong 
SAR, respectively [19,20]. Moreover, the TT marker has the potential 
to be used for detection of silent infection in vaccinated ducks, with 
the development of an anamnestic response to H5 in vaccinated ducks 
infected with HPAI H5N1 virus [20]. Eradication of H5N1 virus from 
ducks requires widespread vaccination, boosters of larger antigen doses, 
preferably before ducks are sent out to graze, and thus segregation of 
poultry species for control programs [21].
In the field, H5/TT positive marker antibody ratios could be used 
to assess whether avian influenza virus marker-vaccinated birds have 
been exposed to field virus post-vaccination, as an anamnestic response 
will likely occur to H5, influenced by antigen diversity between vaccine 
and circulating viruses. If infection travels quickly through the flock, 
it is likely that sufficient poultry will have developed an anamnestic 
response to allow detection of a shift in the flock H5/TT antibody ratio 
before 30% of the flock would have developed an anti-N1 antibody 
response according to a N1-DIVA approach. Evaluation of our field 
trials using chicken farms in Hong Kong SAR, demonstrated successful 
use of the TT marker in a standard inactivated whole H5 avian influenza 
virus vaccine (made in-house with formulated components provided 
by Intervet). Batches of chickens on five chicken farms were routinely 
vaccinated either with inactivated water-in-oil adjuvanted TT/H5N2 
vaccine (n=120 each farm) or H5N2 vaccine (n=12 each farm) at 8-10 
days and 36-38 days of age. Antibody responses in chicks were pre-
tested before vaccination and after the first and second vaccination with 
a final bleed o f chickens at 64 days of age. Pre-vaccination testing for 
H5 HI titres of thirty 8-day old chicks, which were imported as 1-day 
old chicks from mainland China from parent bids vaccinated with H5, 
on each farm showed considerable variation in the level of maternal H5 
antibody titres greater than 16 (ranging from 0-60%). However, by the 
second bleed of these H5 HI positive birds, 86% were H5 HI antibody 
negative suggesting that maternal antibody had waned. The H5 HI 
antibody titres following the first and second vaccination with the TT/
H5N2 and H5N2 vaccines were variable between the five farms but 
reached the national target of at least 70% of the batch responding after 
the two-dose vaccination course with an HI≥20titre.Allofchickens tested 
in this field study had no pre -existing antibody to TT, confirming our 
earlier published reports in chickens [17,18] and no antibody responses 
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to TT were found in the H5N2 vaccinated chickens on the farms. As 
expected, the birds vaccinated with the TT/H5N2 vaccine mounted an 
antibody response to the TT marker. Future field evaluation studies 
are needed to conclusively indicate that there is no interference to 
H5 antibody responses from the TT marker in the combined vaccine 
although our pen-side studies showed no significant interference with 
H6 antibody responses from the TT antigen in a combined LPAI TT/
H6N2 vaccine [17] and no abrogation of protection in H5N2 vaccine/
H5N1 challenge studies of chickens [18]. Outbreak investigations of 
anti-TT antibodies could provide vital information on whether the 
flock is vaccinated and the H5/TT antibody ratios could provide data 
on whether vaccination has been effective and the duration of exposure 
of the flock. We also demonstrated that anti-TT and anti-H5 antibody 
titres could be assessed in dead vaccinated birds [17]. This is useful to 
determine whether a vaccinated bird had died in the flock and the H5/
TT antibody ratio provides data on the level of vaccination and possible 
emergence of an escape variant against which the vaccine would have 
reduced efficacy. Post-vaccination surveillance of birds seronegative to 
a positive marker could be used to determine whether poor response 
to vaccination is due to non-vaccination or infection rather than 
vaccination, especially in ducks, and could be performed before birds 
are sent to market using a simple and inexpensive pen-side test to assess 
antibodies to H5 and TT. A flock trial evaluation study designed for 
either chickens or grazing ducks specifically for Asian versus European 
markets is required as no HPAI virus challenge studies have as yet been 
reported with any DIVA strategy.
Although other positive vaccine markers, such as GFP, have been 
proposed for avian vaccines, the TT positive marker offers improved 
capacity for early detection of an avian influenza virus outbreak 
in the flock, high sensitivity and high throughput testing, low cost 
and virus strain clade-independence. Further advantages of the TT 
marker vaccine include indisputable serological data for surveillance 
programs on whether poultry have been vaccinated in the past and 
on the vaccination status of flocks at the time of an outbreak without 
dependence on dubious certification for compliance with vaccination. 
Current problems associated with existing post-vaccination surveillance 
programs include records of purported vaccination as opposed to 
actual vaccination, vaccination failure due to virus strain mismatch or 
failure to vaccinate where birds are mistakenly missed out, and extent 
of infection in areas where vaccines are being used. Three scenarios are 
envisaged for surveillance of H5N1 virus outbreaks in poultry. Firstly, 
if sentinels are positive to the TT marker and H5 then this indicates 
that they have been inadvertently vaccinated. Secondly, if vaccinated 
poultry are negative to the TT marker but H5 positive then this indicates 
probable vaccine failure and subsequent exposure to field virus. 
Thirdly, if vaccinated poultry are positive to the TT marker and H5 
positive, then the ratio of H5/TT antibodies would assess whether there 
has been possible exposure to field virus, warranting further detailed 
virus investigations. Targeted surveillance in pre-slaughter testing of 
birds could determine vaccination from natural infection empowering 
investigation of H5 virus circulation in bird markets. Also, border 
control for smuggled birds could incorporate positive marker serology 
to check for vaccine-approved animals. Importantly, virus outbreaks 
in vaccinated flocks can be monitored to identify if the field strain is 
overcoming vaccine-induced immunity to the H5 antigen, indicating 
likely emergence of an antigenic variant against which existing vaccines 
are less effective. Although the TT marker vaccine approach does not 
represent a true DIVA strategy, it is nonetheless a profoundly useful 
tool for evaluation of the vaccination process, which is crucial in control 
programs for HPAI H5N1 virus in smallholder poultry sectors. The 
TT positive marker vaccine could potentially provide epidemiological 
data for important decision making on a more focused “risk-based’ 
vaccination campaign to achieve the goal to ultimately reduce the scope 
of vaccination and provide countries with an exit strategy.
In conclusion, vaccines are effective countermeasures and worthy 
investments for control of HPAI H5N1 virus in domestic poultry, 
especially with the lack of immunity in humans to H5-possessing 
influenza viruses. Use of updated vaccines to emerging H5N1 influenza 
viruses circulating in poultry and increased surveillance in regions 
likely to have H5N1 virus outbreaks in flocks using a positive marker 
approach improves monitoring of flocks in control programs. A 
positive marker vaccine strategy using TT for poultry, which targets 
protective efficacy of vaccination coupled with bio-surveillance of 
vaccinated birds and virus outbreaks in flocks, provides both a practical 
and effective option for vaccination campaigns against H5N1 avian 
influenza virus. Future scope of the introduction of such a marker AIV 
vaccine into high risk areas would depend on demonstration of the 
benefits without interference with international trade on a country by 
country basis through future field trials.
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